Oppenheimer Analyst Calls Life Tech Shares Undervalued, Reiterates Outperform Rating | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – An Oppenheimer analyst today called Life Technologies' shares "substantially undervalued" and reiterated an Outperform rating with a $58 price target, noting a return to normalcy in the firm's China business and the potential of the Ion Torrent sequencing platform.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.